Lucideon invests £1.5M to offer pharma testing services

International materials development and testing company Lucideon has added pharmaceutical quality control testing to its range of analytical capabilities.

The £1.5 million investment at its headquarters in Stoke-on-Trent is part of the company’s commitment to providing a comprehensive service for the pharmaceutical, medical devices and consumer healthcare industries.

Facilities include both chemistry and microbiology laboratories providing pharmacopoeial testing (BP, Eur. Ph., USP, JP), quality control (batch release) testing, method development and validation, raw material analysis, stability storage and water testing as well as full microbiology testing including sterility, endotoxin and bioburden determinations.

Dr. Richard White, head of testing, said: “Healthcare is now one of our biggest sectors, due to the work we do with many blue-chip companies worldwide. 

“Our focus is on the provision of a high-quality service and fast turnaround times. We’re unique though in that we don’t just provide routine testing. Thanks to our advanced surface analysis capabilities and innovative materials technologies, we work with clients to develop the products and processes of the future. The pharmaceutical facility is key to that approach.”

Parmjit S Bilan, who heads up the pharmaceutical team, said:  “The new pharmaceutical testing services complement Lucideon’s extensive materials characterisation, analysis and development capabilities. Our clients not only benefit from having access to those capabilities but also from being able to work with a team of experienced scientists who bring cross-industry knowledge and expertise to every project.”

To find out more about Lucideon’s pharmaceutical quality control testing services, visit www.lucideon.com/pharma.